Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Zenarestat

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Diabetes mellitus occurrence has been associated to the modification of the physiological levels of glucose and is often… Expand
2009
2009
The dorsal root ganglia (DRG) have been identified as the target tissue in diabetic somatosensory neuropathy. It has been… Expand
2006
2006
Conduct of a large, multicenter trial of the aldose reductase inhibitor zenarestat provided data on the reproducibility of… Expand
Highly Cited
2004
Highly Cited
2004
OBJECTIVE The aim of this study was to report the baseline and natural progression of diabetic peripheral neuropathy over 12… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2002
2002
The crystal structure of the complex of human recombinant aldose reductase (AR) with zenarestat, one of its potent inhibitors… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2001
2001
The effects of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow (NBF) were explored in streptozotocin-induced… Expand
2000
2000
We studied the effects of zenarestat, an aldose reductase inhibitor (ARI), on peripheral neuropathy in Zucker diabetic fatty (ZDF… Expand
Highly Cited
1999
Highly Cited
1999
Objective: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and… Expand
  • figure 1
  • figure 2
  • table 3
  • table 4
  • figure 3
1994
1994
Abstract— Zenarestat, (3‐(4‐bromo‐2‐fluorobenzyl)‐7‐chloro‐2,4‐dioxo‐1,2,3,4‐tetrahydroquinazolin‐1‐y1) acetic acid, an aldose… Expand
1991
1991
1. Rat shows a marked sex difference in the excretion of 14C-zenarestat: only 1% of the dose was excreted in the urine of males… Expand